Common painkiller may boost lung cancer Drug's power
NCT ID NCT04184921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding aspirin to the targeted drug osimertinib helps control advanced EGFR-positive non-small cell lung cancer. 216 participants received the combination as their first treatment. The goal was to see if it delays cancer progression and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- osimertinib and aspirin
- What this could lead to
- If it works, this combination could help control advanced EGFR-positive lung cancer longer than osimertinib alone.
- What could go wrong
- This is a small, early-phase trial without a comparison group, so results may not confirm benefit. Aspirin also carries bleeding risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER NON-SMALL CELL STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Daping Hospital
Chongqing, Chongqing Municipality, 400000, China